WIN 2016 Symposium in Parijs: “Innovatieve aanpak kan overlevingskans kankerpatiënt verbeteren”
VILLEJUIF, Frankrijk –(BUSINESS WIRE)– WIN 2016 vindt op 27 en 28 juni 2016 plaats in Parijs, Frankrijk. Het is de achtste editie van een succesvolle reeks symposia georganiseerd door het Worldwide Innovative Networking (WIN) Consortium, gewijd aan het bevorderen van kankeronderzoek door wereldwijde samenwerking. Dit jaar richt WIN zich op de kritische vraag hoe innovatief gebruik van gerichte therapieën de overlevingskansen van kankerpatiënten kan verhogen.
Onder voorzitterschap van dr. Josep Tabernero, (Vall d’Hebron, Spanje), presenteert het WIN Symposium een unieke gelegenheid door topexperts met verschillende achtergronden bij elkaar te brengen om zo innovatieve stappen te nemen in de behandeling van kanker en de overlevingskansen van patiënten te verhogen.
WIN 2016 Symposium June 27-28, Paris: “Innovative Approaches to Improve Cancer Patient Outcomes” |
||||||||||||||||||||||
VILLEJUIF, France–(BUSINESS WIRE)– WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8 th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration. Under the chairmanship of Dr. Josep Tabernero, (Vall d’ Hebron, Spain), the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes. Themes that will be addressed:
“ The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials” John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.
|
Check out our twitter: @NewsNovumpr